4-aminopyridine decreases MPTP-induced behavioral disturbances in animal model of Parkinson’s disease
International Clinical Neuroscience Journal,
Vol. 2 No. 4 (2015),
5 May 2016
Background and purpose: Progressive degeneration of dopaminergic neurons in the midbrain is the main mechanism of Parkinson’s disease (PD). Although potassium channels affect neural activity and death in this area, little research has investigated the effect of potassium channel blockers, such as 4-aminopyridine in the pretreatment of PD.
Methods: Fifty-six healthy male Wistar rats were selected for this study. They were divided into seven groups according to receiving saline or 4-aminopyridine, receiving a low or high dose of 4-aminopyridine and receiving 4-aminopyridine for short or long periods. Apomorphine-induced rotational test, elevated body swing test and rotarod test were done to examine behavioral performances.
Results: 4-aminopyridine could not completely block behavioral disturbances induced by MPTP, however, it decreased them in all behavioral tests. Long administration of 4-aminopyridine was more effective than short administration in lowering behavioral disturbances. Although high dose of 4-aminopyridine was more effective than low dose in initial trials of each behavioral test, there was no difference between them in the last trial.
Conclusion: Long administration of low dose of 4-aminopyridine is the best way to lessen behavioral disturbances induce by MPTP and also avoiding side effects of high dose of 4-aminopyridine.
- Parkinson’s disease
- behavioral tests
How to Cite
Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? Journal of Neurology, Neurosurgery & Psychiatry. 2000;69(3):308-12.
Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Archives of neurology. 2011;68(2):165-.
Duker AP, Espay AJ. Surgical treatment of Parkinson disease: past, present, and future. Neurologic clinics. 2013;31(3):799-808.
Aquino CC, Fox SH. Clinical spectrum of levodopa‐induced complications. Movement Disorders. 2015;30(1):80-9.
Tian C, Zhu R, Zhu L, Qiu T, Cao Z, Kang T. Potassium channels: structures, diseases, and modulators. Chemical biology & drug design. 2014;83(1):1-26.
Yu SP, Yeh CH, Gottron F, Wang X, Grabb MC, Choi DW. Role of the Outward Delayed Rectifier K+ Current in Ceramide‐Induced Caspase Activation and Apoptosis in Cultured Cortical Neurons. Journal of neurochemistry. 1999;73(3):933-41.
Wolfe D, Hayes K, Hsieh J, Potter P. Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury: a double-blinded, placebo-controlled crossover trial. Journal of neurotrauma. 2001;18(8):757-71.
Leung G, Sun W, Brookes S, Smith D, Shi R. Potassium channel blocker, 4-aminopyridine-3-methanol, restores axonal conduction in spinal cord of an animal model of multiple sclerosis. Experimental neurology. 2011;227(1):232-5.
Franciosi S, Ryu JK, Choi HB, Radov L, Kim SU, McLarnon JG. Broad-spectrum effects of 4-aminopyridine to modulate amyloid β1–42-induced cell signaling and functional responses in human microglia. The Journal of neuroscience. 2006;26(45):11652-64.
Luca CC, Singer C. Can 4-aminopyridine modulate dysfunctional gait networks in Parkinson's disease? Parkinsonism & related disorders. 2013;19(9):777-82.
Moriguchi S, Yabuki Y, Fukunaga K. Reduced calcium/calmodulin‐dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in MPTP‐treated mice. Journal of neurochemistry. 2012;120(4):541-51.
Fujita M, Nishino H, Kumazaki M, Shimada S, Tohyama M, Nishimura T. Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned rat. Molecular brain research. 1996;39(1):127-36.
Borlongan CV, Randall TS, Cahill DW, Sanberg PR. Asymmetrical motor behavior in rats with unilateral striatal excitotoxic lesions as revealed by the elevated body swing test. Brain research. 1995;676(1):231-4.
Lundblad M, Vaudano E, Cenci M. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW‐6002 in a rat model of l‐DOPA‐induced dyskinesia. Journal of neurochemistry. 2003;84(6):1398-410.
Wang Y, Yang P-l, Tang J-f, Lin J-f, Cai X-h, Wang X-t, et al. Potassium channels: possible new therapeutic targets in Parkinson’s disease. Medical hypotheses. 2008;71(4):546-50.
Liss B, Haeckel O, Wildmann J, Miki T, Seino S, Roeper J. K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nature neuroscience. 2005;8(12):1742-51.
Noh J, Chang S, Wang S, Chung J. Dual function of Zn 2+ on the intrinsic excitability of dopaminergic neurons in rat substantia nigra. Neuroscience. 2011;175:85-92.
Ogita K, Okuda H, Watanabe M, Nagashima R, Sugiyama C, Yoneda Y. In vivo treatment with the K+ channel blocker 4-aminopyridine protects against kainate-induced neuronal cell death through activation of NMDA receptors in murine hippocampus. Neuropharmacology. 2005;48(6):810-21.
Jin S, Fredholm B. Role of NMDA, AMPA and kainate receptors in mediating glutamate-and 4-AP-induced dopamine and acetylcholine release from rat striatal slices. Neuropharmacology. 1994;33(9):1039-48.
Luhmann H, Dzhala V, Ben‐Ari Y. Generation and propagation of 4‐AP‐induced epileptiform activity in neonatal intact limbic structures in vitro. European Journal of Neuroscience. 2000;12(8):2757-68.
Claassen J, Spiegel R, Kalla R, Faldon M, Kennard C, Danchaivijitr C, et al. A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus—effects on slowphase eye velocity, postural stability, locomotion and symptoms. Journal of Neurology, Neurosurgery & Psychiatry. 2013;84(12):1392-9.
- Abstract Viewed: 469 times
- PDF Downloaded: 184 times